Medicare adds cancer screening test, but phases in over 20 years

What it does

This bill adds Medicare coverage for multi-cancer early detection screening tests (blood tests that screen for multiple cancer types at once) starting January 1, 2028. Medicare will pay for these tests if they are FDA-cleared or approved, use genomic sequencing of blood samples, and the Secretary determines they are medically necessary. Coverage is limited by age (starting at 68 in 2028, increasing by one year annually) and frequency (no more than once per 11 months), with payment initially set to match the current rate for colorectal screening DNA tests.

Why we flagged it

The bill's core function is to add a new preventive screening test to Medicare's covered services. It is a straightforward benefit expansion, not a deregulation, subsidy carve-out, or liability shield. The named-after-person framing is secondary to the substantive policy.

What the text implies

• Payment rate is initially pegged to colorectal DNA screening (current rate), but after 2031 shifts to a competitive bidding process (section 1834A), which may lower reimbursement and affect test availability.
• Age-based phase-in (68 in 2028, rising 1 year annually) means full Medicare population coverage will not occur until 2048, creating a 20-year ramp-up period during which younger seniors are excluded.
• Secretary retains sole discretion to determine whether a test is 'reasonable and necessary' — no statutory standard beyond FDA clearance, creating regulatory uncertainty for test developers.
• Once USPSTF issues a grade A or B recommendation, the age and frequency limits disappear (section 1834(aa)(3)), potentially creating a cliff where coverage suddenly expands without additional appropriation.
• Bill does not specify funding source or appropriation, leaving cost to be absorbed within existing Medicare Part B budget.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries gain access to a new preventive screening technology with no out-of-pocket cost (Medicare covers it), though access is phased in by age and frequency-limited. The bill does not restrict existing cancer screening coverage, so it is purely additive to current benefits.

Who stands to gain

• in vitro diagnostic (IVD) manufacturers developing multi-cancer screening tests
• genomic sequencing laboratories
• clinical laboratory service providers

Named in the bill

Medicare (Centers for Medicare & Medicaid Services), Social Security Act, Title XVIII, FDA (Food and Drug, and Cosmetic Act sections 510(k), 513(f)(2), 515), United States Preventive Services Task Force (USPSTF), Section 1861 (Medicare covered services), Section 1834 (Medicare payment rules), Section 1833 (Medicare coinsurance and deductibles), Section 1862 (Medicare exclusions)

Where it stands

68 cosponsors: 35 Democrats, 32 Republicans, 1 Independents.

• Jan 30, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 30, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

11 lobbying clients named this bill on 15 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,854,304 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 92% of bills with at least one filing.

Mike Crapo, the sponsor, reported $552,275 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $2,380,000 on 1 filing
• Grail, Inc. (formerly Grail, Llc) — $1,260,000 on 2 filings
• American Association of Nurse Practitioners — $950,000 on 2 filings
• Boehringer Ingelheim USA Corporation — $710,000 on 1 filing
• International Association of Fire Fighters — $184,304 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.